Genexine Bilan de santé

Santé financière contrôle des critères 4/6

Genexine possède un total de capitaux propres de ₩288.1B et une dette totale de ₩68.5B, ce qui porte son ratio d'endettement à 23.8%. Son actif total et son passif total sont ₩365.4B et de ₩77.3B.

Informations clés

23.8%

Ratio d'endettement

₩68.53b

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	₩52.50b
Fonds propres	₩288.07b
Total du passif	₩77.32b
Total des actifs	₩365.39b

Mises à jour récentes de la santé financière

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Jul 12

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Recent updates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Jul 12

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de A095700 ( ₩66.7B ) dépassent ses passifs à court terme ( ₩51.8B ).

Passif à long terme: Les actifs à court terme de A095700 ( ₩66.7B ) dépassent ses passifs à long terme ( ₩25.5B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de A095700 ( 5.6% ) est considéré comme satisfaisant.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de A095700 a diminué au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: A095700 dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: A095700 dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 5.7 % chaque année

Genexine Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Recent updates

New minor risk - Shareholder dilution

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

New minor risk - Revenue size

New minor risk - Share price stability

Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority (BPOM)

Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study

Ajinomoto Co., Inc. (TSE:2802) agreed to acquire remaining 25% stake in Ajinomoto Genexine Co., Ltd from Genexine, Inc. (KOSDAQ:A095700) for KRW 19.3 billion.

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for Advanced Cervical Cancer

Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

Genexine, Inc. has completed a Follow-on Equity Offering in the amount of KRW 82.044713 billion.

No independent directors

Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc., Annual General Meeting, Mar 29, 2021

New 90-day low: ₩94,300

Turret Capital Management Signs A Definitive License Agreement with Genexine, Inc

New 90-day low: ₩103,600

Genexine, Inc. and NeoimmuneTech, Inc. Releases Data for Their Phase 1B/2 Study of Gx-I7/Nt-I7 and Keytruda® in Patients with Triple-Negative Breast Cancer

New 90-day low: ₩104,000

New 90-day low: ₩109,500

Genexine, Inc. announced that it has received KRW 3.29761 billion in funding from Handok, Inc.

New 90-day high - ₩132,000

New 90-day high - ₩130,600

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines